IP Library Granted Patent US 10,265,258
Granted Patent B2
US 10,265,258 · App. 15/668,814 · Granted Apr 23, 2019

Methods for treating hair loss disorders

Inventors: Angela M. Christiano (Mahwah, NJ); Raphael Clynes (West Nyack, NY)
Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
A61K8/4953A61K8/41A61K8/64A61K31/137A61K31/277A61K31/407A61K31/437A61K31/506A61K31/519A61K31/52A61K31/529A61K31/5377A61K31/553A61K31/63A61K31/7052A61K31/713A61Q7/00A61K2800/782
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,265,258
App. No.
15/668,814
Granted
Apr 23, 2019
Kind
B2
Abstract

The invention provides for methods for treating a hair loss disorder in a subject by administering a Janus Kinase/Signal Transducers and Activators of Transcription inhibitor.

Claims (31)

1. A method of treating alopecia areata in a human in need thereof comprising administering to the human an effective amount of a Janus kinase (JAK) inhibitor having the following structure:

2. The method of claim 1 , wherein the alopecia areata is patchy alopecia areata.

3. The method of claim 1 , wherein the alopecia areata is alopecia totalis.

4. The method of claim 1 , wherein the alopecia areata is alopecia universalis.

5. The method of claim 1 , wherein the effective amount of the JAK inhibitor is administered topically.

6. The method of claim 1 , wherein the effective amount of the JAK inhibitor is administered orally.

7. The method of claim 1 , wherein administering to the human occurs in a route selected from intra-muscular injection, intra-peritoneal injection, an infusion, intravenous, intradermal, subcutaneous, oral, inhalation, transdermal, topical, transmucosal, nasal and rectal.

8. The method of claim 1 , wherein the JAK inhibitor is administered to the human in a pharmaceutical composition selected from a solution, suspension, capsule, tablet, pill, troche, nasal spray, suppository, ointment, salve, gel, and cream.

9. The method of claim 1 , wherein administering to the human occurs twice daily, daily, weekly, twice weekly, monthly, twice monthly, yearly, 1 time per week, 2 times per week, 3 times per week, 4 times per week, 5 times per week, 6 times per week, 7 times per week, 8 times per week, 9 times per week, 10 times per week, 11 times per week, 12 times per week, 13 times per week, or 14 times per week.

10. The method of claim 1 , wherein the JAK inhibitor includes an isotope.

11. The method of claim 1 , wherein the JAK inhibitor includes one or more isotopes of carbon or hydrogen.

12. The method of claim 1 , wherein the method further comprises administering a second JAK inhibitor to said human.

13. The method of claim 1 , wherein the JAK inhibitor is the sole therapeutically active ingredient administered to said human for treating alopecia areata.

14. The method of claim 1 , wherein treating alopecia areata is inducing hair growth.

15. The method of claim 10 , wherein the compound is suitable for nuclear magnetic resonance (NMR).

16. The method of claim 10 , wherein the isotope is a radioisotope.

17. The method of claim 10 , wherein the alopecia areata is patchy alopecia areata.

18. The method of claim 10 , wherein the alopecia areata is alopecia totalis.

19. The method of claim 10 , wherein the alopecia areata is alopecia universalis.

20. The method of claim 10 , wherein the JAK inhibitor is administered topically.

21. The method of claim 10 , wherein JAK inhibitor is administered orally.

22. The method of claim 11 , wherein the JAK inhibitor is suitable for NMR.

23. The method of claim 11 , wherein the isotope is a radioisotope.

24. The method of claim 11 , wherein the alopecia areata is patchy alopecia areata.

25. The method of claim 11 , wherein the alopecia areata is alopecia totalis.

26. The method of claim 11 , wherein the alopecia areata is alopecia universalis.

27. The method of claim 11 , wherein the JAK inhibitor is administered topically.

28. The method of claim 11 , wherein the JAK inhibitor is administered orally.

29. The method of claim 1 , wherein the JAK inhibitor is in a topical pharmaceutical composition at a concentration selected from about 0.1%, about 0.2%, about 0.3%, about 0.4%, about 0.5%, about 0.6%, about 0.7%, about 0.8%, about 0.9%, about 1.0%, about 1.1%, about 1.2%, about 1.3%, about 1.4%, about 1.5%, about 1.6%, about 1.7%, about 1.8%, about 1.9%, about 2.0%, about 2.1%, about 2.2%, about 2.3%, about 2.4%, about 2.5%, about 2.6%, about 2.7%, about 2.8%, about 2.9%, about 3.0%, about 3.5%, about 4%, about 4.5%, about 5%, about 5.5%, about 6%, about 6.5%, about 7%, about 7.5%, about 8%, about 8.5%, about 9%, about 9.5%, or about 10%.

30. The method of claim 1 , wherein the effective amount of the JAK inhibitor administered to the subject is selected from about 0.0001 μg/kg body weight, about 0.00025 μg/kg body weight, about 0.0005 μg/kg body weight, about 0.00075 μg/kg body weight, about 0.001 μg/kg body weight, about 0.0025 μg/kg body weight, about 0.005 μg/kg body weight, about 0.0075 μg/kg body weight, about 0.01 μg/kg body weight, about 0.025 μg/kg body weight, about 0.05 μg/kg body weight, about 0.075 μg/kg body weight, about 0.1 μg/kg body weight, about 0.25 μg/kg body weight, about 0.5 μg/kg body weight, about 0.75 μg/kg body weight, about 1 μg/kg body weight, about 5 μg/kg body weight, about 10 μg/kg body weight, about 25 μg/kg body weight, about 50 μg/kg body weight, about 75 μg/kg body weight, about 100 μg/kg body weight, about 150 μg/kg body weight, about 200 μg/kg body weight, about 250 μg/kg body weight, about 300 μg/kg body weight, about 350 μg/kg body weight, about 400 μg/kg body weight, about 450 μg/kg body weight, about 500 μg/kg body weight, about 550 μg/kg body weight, about 600 μg/kg body weight, about 650 μg/kg body weight, about 700 μg/kg body weight, about 750 μg/kg body weight, about 800 μg/kg body weight, about 850 μg/kg body weight, about 900 μg/kg body weight, about 950 μg/kg body weight, about 1000 μg/kg body weight, about 2000 μg/kg body weight, about 3000 μg/kg body weight, about 4000 μg/kg body weight, about 5000 μg/kg body weight, about 6000 μg/kg body weight, about 7000 μg/kg body weight, about 8000 μg/kg body weight, about 95000 μg/kg body weight, or about 10,000 μg/kg body weight, about 1 mg/kg body weight, about 1.5 mg/kg body weight, about 2 mg/kg body weight, about 2.5 mg/kg body weight, about 3 mg/kg body weight, about 3.5 mg/kg body weight, about 4 mg/kg body weight, about 4.5 mg/kg body weight, about 5 mg/kg body weight, about 5.5 mg/kg body weight, about 6 mg/kg body weight, about 6.5 mg/kg body weight, about 7 mg/kg body weight, about 7.5 mg/kg body weight, about 8 mg/kg body weight, about 9.5 mg/kg body weight, about 10 mg/kg body weight, about 10.5 mg/kg body weight, about 11.0 mg/kg body weight, about 11.5 mg/kg body weight, about 12 mg/kg body weight, about 12.5 mg/kg body weight, about 13 mg/kg body weight, about 13.5 mg/kg body weight, about 14 mg/kg body weight, about 14.5 mg/kg body weight, about 15 mg/kg body weight, about 15.5 mg/kg body weight, about 16 mg/kg body weight, about 16.5 mg/kg body weight, about 17 mg/kg body weight, about 17.5 mg/kg body weight, about 18 mg/kg body weight, about 19.5 mg/kg body weight, about 20 mg/kg body weight, about 21.5 mg/kg body weight, about 22 mg/kg body weight, about 22.5 mg/kg body weight, about 23 mg/kg body weight, about 23.5 mg/kg body weight, about 24 mg/kg body weight, about 24.5 mg/kg body weight, about 25 mg/kg body weight, about 25.5 mg/kg body weight, about 26 mg/kg body weight, about 26.5 mg/kg body weight, about 27 mg/kg body weight, about 27.5 mg/kg body weight, about 28 mg/kg body weight, about 29.5 mg/kg body weight, or about 30 mg/kg body weight.

31. The method of claim 1 , wherein administering to the subject occurs for at least 1 week.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 8, 2018
From: CHRISTIANO, ANGELA M.; CLYNES, RAPHAEL
To: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
Reel/Frame 044871/0637 →
Continuity (8)
Continuation 14821623 · Aug 7, 2015
Continuation 13886252 · May 2, 2013
Continuation In Part PCTUS2011059029 · Nov 2, 2011
Continuation In Part PCTUS2013034688 · Mar 29, 2013
Provisional Application 61409509 · Nov 2, 2010
Provisional Application 61617225 · Mar 29, 2012
Provisional Application 61645499 · May 10, 2012
Related Publication 20180021235A1 · Jan 25, 2018
Cited By (1)
US 12,285,432